BROCHURE SUPPLEMENT

(Part 2B of Form ADV)

October 28, 2026

Matthew P. Jones, Ph.D.

ROCKETTRADER, INC.
dba Quants Compete
785 Old Hickory Blvd., Suite 301
Brentwood, TN 37027
Phone: (334) 332-3007
Email: matthew.jones@quantscompete.com

This brochure supplement provides information about Matthew P. Jones, Ph.D. (CRD# 7351426) that supplements RocketTrader, Inc. dba Quants Compete ("Quants") Form ADV Part 2A Disclosure Brochure (the "Brochure"). You should have received a copy of that Brochure. Please contact us at **(334) 332-3007** if you did not receive Quants' Brochure or if you have any questions about the contents of this supplement.

Additional information about Quants (CRD #313310) is also available on the SEC's website at www.adviserinfo.sec.gov.

ITEM 1: COVER PAGE

Please see previous page.

ITEM 2: EDUCATIONAL BACKGROUND AND BUSINESS EXPERIENCE

Matthew P. Jones, Ph.D. (DOB: 1978)

Educational Background:

- Bachelor of Science, Mechanical Engineering, Clemson University – South Carolina, 2000
- Master of Science, Mechanical Engineering, Clemson University – South Carolina, 2004
- Doctor of Philosophy (Ph.D.), Physics, Auburn University – Alabama, 2011
- Graduate Certificate, Project Management, Boston University – Massachusetts (2020)
- FINRA Series 65
- FINRA SIE

Business Background:

- Cox Private Capital / Cox Management Partners – Managing Partner/Chief Compliance Officer (01/2024 – 02/2025)
- RocketTrader, Inc. dba Quants Compete – Chief Financial Officer, Chief Executive Officer and Chief Compliance Officer (02/2021 – Present)
- Collins Aerospace – Senior Systems Engineer (01/2017 – 03/2022)

ITEM 3: DISCIPLINARY INFORMATION

Quants is required to disclose all material facts regarding any legal or disciplinary event that would be material to a client's evaluation of each investment person that provides advice to each client. On June 15, 2026, Dr. Jones, individually and as principal of Quants Compete (RocketTrader, Inc.), consented to the entry of a Consent Order by the Tennessee Department of Commerce and Insurance, Securities Division (Matter No. 25-0002283). The order resolved administrative and recordkeeping findings from the firm's first cyclical examination, each of which was corrected during the examination. The order required compliance with the Tennessee Securities Act going forward, a $3,000 civil penalty (joint and several with the firm), and completion by Dr. Jones of 12 hours of NASAA-approved continuing education. The order did not involve any finding of fraud, manipulation, or deceptive conduct.

ITEM 4: OTHER BUSINESS ACTIVITIES

Matthew P. Jones, Ph.D. divides his professional time between the investment advisory services provided under the Quants Compete name and the outside business activities described below, including approximately 50% of his professional time devoted to BotIQ LLC.

Dr. Jones is also the founder and managing member of BotIQ LLC, a wholly-owned Delaware subsidiary of RocketTrader Inc. BotIQ LLC operates a managed artificial intelligence automation platform designed for small businesses, providing AI-powered business automation services including automated client communications, appointment and booking integrations, and operational workflow automation across a range of service industry verticals. BotIQ LLC is not an investment advisory business and its services are entirely separate from the investment advisory services provided under the Quants Compete name. Dr. Jones' involvement in BotIQ LLC represents a material outside business activity. Approximately 50% of Dr. Jones' professional time is devoted to BotIQ LLC, and competing time demands could affect the quality or timeliness of investment advisory services. Clients should be aware of this material time commitment to an outside business activity. See Item 10.D of the Firm's Form ADV Part 2A for a full

description of BotIQ LLC and related conflicts of interest. BotIQ services are accessible at botiq.rockettrader.com.

ITEM 5: ADDITIONAL COMPENSATION

Matthew P. Jones, Ph.D. may receive compensation for his ownership interest in Quants, for which he is the majority shareholder and serves as the Chief Financial Officer, Chief Executive Officer, and Chief Compliance Officer. Matthew P. Jones, Ph.D. does not receive any other economic benefits, sales awards, or other compensation in connection with providing advisory services to clients. Clients should be aware of the following related-party relationships involving advisory clients of the Firm: (i) effective March 2, 2026, advisory client Mitchell Munson became an equity holder in RocketTrader Inc., acquiring 1,506 shares of Class B Common Stock with the right to purchase up to 20,000 total Class B shares at $2.00 per share over five years — this creates a conflict of interest as the Firm has a financial incentive to retain and grow Mr. Munson's advisory assets, which indirectly benefits the value of his equity; and (ii) effective January 16, 2025, advisory client Donna Thiel, the mother-in-law of Dr. Jones, provided a $10,000.00 loan to RocketTrader Inc. at 5.00% per annum pursuant to a written promissory note maturing December 31, 2026 — this creates a conflict of interest as the Firm has a financial obligation to Ms. Thiel as a creditor and a personal family relationship with her through its principal. Both relationships are fully disclosed in Items 10.B, 10.E, and 11.B of the Firm's Form ADV Part 2A.

ITEM 6: SUPERVISION

Matthew P. Jones, Ph.D. is the majority shareholder of Quants and serves as the Chief Financial Officer, Chief Executive Officer, and Chief Compliance Officer. As such, he is ultimately responsible for all advice provided to its clients as further described in the Brochure. Matthew P. Jones, Ph.D. can be contacted at (334) 332-3007.

ITEM 7: REQUIREMENTS FOR STATE-REGISTERED ADVISORS

Matthew P. Jones, Ph.D. has been involved in one administrative proceeding. On June 15, 2026, Dr. Jones consented to the entry of a Consent Order by the Tennessee Department of Commerce and Insurance, Securities Division (Matter No. 25-0002283), resolving administrative and recordkeeping findings from the firm's first cyclical examination. The order did not involve any finding of fraud, manipulation, or deceptive conduct. See Item 3 above for full details. Dr. Jones has NOT been involved in an arbitration, civil proceeding, self-regulatory proceeding, or a bankruptcy petition.